rss
J Neurol Neurosurg Psychiatry 2007;78:939-943 doi:10.1136/jnnp.2006.103309
  • Paper

Psychiatric disorders in preclinical Huntington’s disease

  1. Camille L Julien1,
  2. Jennifer C Thompson1,
  3. Sue Wild2,
  4. Pamela Yardumian2,
  5. Julie S Snowden1,
  6. Gwen Turner2,
  7. David Craufurd3
  1. 1Cerebral Function Unit, Greater Manchester Neuroscience Centre, Hope Hospital, Salford, UK
  2. 2Department of Clinical Genetics, St James’ Hospital, Leeds, UK
  3. 3Academic Unit of Medical Genetics and Regional Genetic Service, University of Manchester and St Mary’s Hospital, Manchester, UK
  1. Correspondence to:
 Dr David Craufurd
 Academic Unit of Medical Genetics and Regional Genetic Service, St Mary’s Hospital, Hathersage Road, Manchester M13 0JH, UK; david.craufurd{at}manchester.ac.uk
  • Received 7 August 2006
  • Accepted 23 November 2006
  • Revised 17 November 2006
  • Published Online First 18 December 2006

Abstract

Background: Psychiatric symptoms are a common feature of Huntington’s disease (HD) and often precede the onset of motor and cognitive impairments. However, it remains unclear whether psychiatric changes in the preclinical period result from structural change, are a reaction to being at risk or simply a coincidental occurrence. Few studies have investigated the temporal course of psychiatric disorder across the preclinical period.

Objectives: To compare lifetime and current prevalence of psychiatric disorder in presymptomatic gene carriers and non-carriers and to examine the relationship of psychiatric prevalence in gene carriers to temporal proximity of clinical onset.

Methods: Lifetime and current psychiatric histories of 204 at risk individuals (89 gene carriers and 115 non-carriers) were obtained using a structured clinical interview, the Composite International Diagnostic Interview. Psychiatric disorders were classified using both standardised diagnostic criteria and a more subtle symptom based approach. Follow-up of gene carriers (n = 51) enabled analysis of the role of temporal proximity to clinical onset.

Results: Gene carriers and non-carriers did not differ in terms of the lifetime frequency of clinical psychiatric disorders or subclinical symptoms. However, gene carriers reported a significantly higher rate of current depressive symptoms. Moreover, the rate of depression increased as a function of proximity to clinical onset.

Conclusions: Affective disorder is an important feature of the prodromal stages of HD. The findings indicate that depression cannot be accounted for by natural concerns of being at risk. There is evidence of a window of several years in which preclinical symptoms are apparent.

Footnotes

  • See Editorial Commentary, p 913

  • Published Online First 18 December 2006

  • Competing interests: None.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs